Rationale: Approximately 40% of hypertrophic cardiomyopathy (HCM) is caused by heterozygous missense mutations in β-cardiac myosin heavy chain (β-MHC). Associating disease phenotype with mutation is confounded by extensive background genetic and lifestyle/environmental differences between subjects even from the same family.
H ypertrophic cardiomyopathy (HCM) is the most frequent inherited disease of the heart. It is caused by missense mutations located in 1 of ≥8 different sarcomere genes. 1 In ≈40% of cases, the defect is attributable to 1 of >300 known single amino acid substitutions in the β-cardiac myosin heavy chain (MHC; Figure 1 ) head domain. 2, 3 Hearts bearing β-MHC mutations usually start to develop significant thickening of ventricular walls and progressive myocardial fibrosis during the second decade of life. 4 Because cardiac function is not compromised at early stages of HCM, affected individuals are often unaware of the disease until complications arise such as life-threatening arrhythmia and heart failure.
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Certain β-MHC mutations are associated with a more severe clinical course than others. 5 Accordingly, they can be graded in benign and malignant mutations to predict disease progression and to stratify the clinical follow-up and medical treatment including implantable cardioverter-defibrillators for primary prevention of sudden death. For example, individuals affected with an Arg453Cys (RC) or an Arg719Trp (RW) mutation have severe myocardial remodeling and die at an average age of only 40 years. 6, 7 On the contrary, normal life expectancy was reported for 3 families carrying Val606Met (VM) mutation. 6 However, many subsequent studies have questioned the benign nature of the VM mutation because they collectively identified ≥8 cases of cardiac death before the age of 30 years in 4 families that comprised 29 carriers of the mutation. [8] [9] [10] [11] [12] Whether the VM mutation per se is associated with a good or a poor prognosis of affected people remains uncertain.
Several factors have been associated with mutations that cause poor prognosis in patients with HCM. First, mutations that alter the charge of the encoded amino acid generally have a worse prognosis than mutations that encode amino acids of the same charge as the normal residue. 7 Second, the location of the affected amino acids in specific functional myosin head domains such as the actin and ATP-binding sites or the converter domain at the head-rod junction has been associated with bad outcome (Figure 1 ). 13 The VM mutation fulfills neither of these criteria raising the question, how a conservative amino acid substitution in the backbone of the cardiac myosin head may cause severe cardiac remodeling and premature death. The diversity of phenotypes between different kindreds and among affected family members suggests that the genotype-phenotype correlation of the VM mutation is highly influenced either by modifying genes or by nongenetic factors or both.
Dissecting the mechanisms that modify the response to a β-MHC mutation has been hindered by the limited number of affected individuals. Therefore, we have begun to evaluate the consequences of expressing the human β-MHC mutation VM in mice and compared the fate of the VM mutation with 2 previously described mouse models that carry human β-MHC mutations, RC and RW, in the mouse α-MHC gene. 14, 15 All mutation-carrying mice were bred on the same genetic background and animals were housed under identical conditions from birth to death to reduce possible differences in background genetic modifiers and to minimize environmental influences. Furthermore, homozygous and compound heterozygous mice were cross-bred to determine the phenotypic consequences of a second mild or severe mutation in the myosin head. While heterozygous 26-week-old RC and RW mutants gradually developed hallmarks of HCM, no phenotype was detected in age-matched VM mice confirming the benign nature of this mutation. By contrast, mice carrying VM with either RC or RW mutations were much more severely affected. That is, even mild mutations substantially aggravated the morphological and functional heart phenotype and significantly reduce survival when placed in trans to more severe mutations. Extending these findings to humans, the huge impact of additional amino acid substitutions within the myosin head would suggest genetic testing of every patient harboring an HCM causing β-MHC mutation for additional genetic variants within this gene to better evaluate the clinical prognosis.
Methods
Detailed Methods are available in the Online Data Supplement, which includes the generation of gene-targeted animal models, cyclosporine A treatment, histological analyses using hematoxylin and eosin, Masson trichrome, Sirius Red, von Kossa, wheat germ agglutinin, and Hoechst 33258 staining as well as terminal deoxyuridine-5'-triphosphate (dUTP) nick-end labeling assays, assessment of myocyte size, mouse echocardiography, quantitative real-time polymerase chain reaction, left ventricular catheterization for assessment of hemodynamics, tissue bath measurements of force generation, transcriptional profiling using Affymetrix microarray, and statistical analysis.
Results

Mice Bearing Human β-MHC Mutations in α-MHC Develop Hallmarks of HCM
The HCM causing amino acid substitutions MHC arginine 453 cysteine substitution (RC), MHC arginine 719 tryptophane substitution (RW), and MHC valine 606 methionine substitution (VM) were introduced into the α-MHC gene of mice. Heterozygous animals bearing the RC/+ or RW/+ mutation showed progressive concentric hypertrophy ( Figure 2 ). Although indistinguishable at young age, left ventricular wall thickness of 26-week-old hearts exceeded that of wild-type (wt) littermates by >20% (P<0.05). At this age, hallmarks of HCM such as myofiber disarray and interstitial fibrosis were also detected ( Figure 2A ). Regardless of morphological alterations, contractile function was good, at 26 weeks of age fractional shortening was 38±3% in wt mice, 43±3% in RW/+, and 49±5% in RC/+ (P<0.05; Figure 2B and Table) . At age 78 weeks, concentric hypertrophy of RC/+ and RW/+ hearts had further progressed, albeit at slower pace ( Figure 2B ). Fractional shortening was unchanged. The slow progression of disease during adolescence, the development of significant cardiac hypertrophy, fibrosis and myofiber disarray in hearts with intact contractile function closely mimic the pathology observed in humans affected with the RC/+ or RW/+ mutation in the β-MHC gene. 6, 7 
α-MHC VM Mutation Produces Mild HCM That Can Be Exacerbated With Cyclosporine
To assess the severity of the VM/+ mutation, a novel knock-in mouse model was generated (Online Figure I ). Unlike RC/+ and RW/+, mice carrying a VM/+ mutation in the α-MHC gene were indistinguishable from wt littermates throughout life ( Figure 2 , Figure 2B , Online Figure II ). Invasive hemodynamic measurements in 8-week-old animals also yielded comparable values for left ventricular pressures, contraction and relaxation in VM/+, and wt mice ( Figure 3C ). Previous studies have demonstrated that cyclosporine exacerbates the hypertrophic response to MHC missense mutations. 16, 17 The response of VM/+ mice to cyclosporine was assessed ( Figure 3A and 3B). After 3 weeks of cyclosporine treatment, VM/+ mice developed symmetrical left ventricular wall thickening (P<0.05) compared with wt mice.
The benign nature of the VM substitution was further evaluated in homozygous animals (VM/VM) generated by crossbreeding of VM/+ mice ( Figure 3C and 3D, Table) . VM/VM mice developed normally. Morphology and function of VM/ VM hearts (left ventricular anterior wall thickness, 0.71±0.03 mm; left ventricular end-diastolic diameter, 3.01±0.13 mm; fractional shortening, 35±5%; P=NS) did not significantly differ from wt or VM/+ hearts ( Figure 4B , Table) . Taken together, in our hands the hypertrophic stimulus of the VM substitution in mouse hearts was below detection limits.
Unlike VM/VM, Homozygous RC/RC and RW/RW Die Early
Inbreeding of RC/+ mice or RW/+ produced wt, heterozygous, and homozygous offsprings at expected ratios (1:2:1). RC/+ and RW/+ animals lived for ≈2 years. In contrast, 100% of mice homozygous for either of the 2 HCM causing mutations (RC/RC and RW/RW) died within 9 days after birth ( Figure 4A ). Cardiac ventricles harvested shortly before death revealed significant upregulation of genetic markers of hypertrophy ( Figure 4B ). At the age of 7 days, atrial and brain natriuretic peptides did not significantly change in heterozygous hearts (maximum, 1.6±0.2-fold over wt), but were strongly upregulated in homozygous hearts (16.8±1.9-fold and 11.2±3.5-fold for atrial natriuretic peptide (P<0.001), 6.8±0.6-fold and 4.5±0.7-fold for brain natriuretic peptide (P<0.001). Morphologically, 1-week-old RC/RC and RW/RW hearts showed hypertrophy of all cardiac chambers ( Figure 4C ; matching data of RW/RW homozygotes not shown). In particular, the atria were enlarged, most likely caused by increased filling pressures and heart failure. Histological examination demonstrated myocyte disarray. Substantial collagen depositions-as in aging heterozygous mutants-were not observed in 7-day-old hearts. Homozygous mutant hearts displayed patches of dying myocardial cells as suggested by increased numbers of terminal dUTP nick-end labeling-positive myocytes (data not shown) and areas in the myocardium with calcifications ( Figure 4D ).
Compound Heterozygous Myosin Mutants (VM/RC) Develop Severe HCM
Next, we investigated the phenotype of mouse hearts carrying 1 benign (VM) and 1 malignant (RC) HCM causing myosin mutation. Cross-breeding of VM/VM and RC/+ mutants produced compound heterozygous VM/RC and VM/+ mice at 1:1 ratios. VM/RC developed normally and body weight did not differ from wt and heterozygous littermates (data not shown). Unlike RC/RC and RW/RW mice, VM/RC mutants lived to adulthood, but died prematurely at a mean age of 62±8 weeks, whereas wt and all heterozygous mouse lines lived for >100 weeks on average ( Figure 5 ).
Histology of VM/RC myocardium was characterized by massive fibrosis, which was already detectable at the age of 10 weeks and progressed further over time ( Figure 6A ). Both at 10 and 26 weeks, collagen depositions in VM/RC hearts were ≈10fold higher than in the hearts of VM/+ littermates (P<0.01). Hypertrophy of VM/RC hearts rapidly progressed and exceeded the wall thickness of VM/+ hearts by >50% at the age of 26 weeks ( Figure 6A and 6B, Table) . Compared with VM/+ siblings and wt hearts, left ventricular wall thickness of VM/ RC heart was almost doubled (P<0.001). Heart-to-body weight ratios (6.7±0.5 mg/g) were higher than in wt (4.7±0.2 mg/g) and single heterozygous animals (VM/+, 4.5±0.1 mg/g; RC/+, 5.2±0.3 mg/g; P<0.05). Individual myocytes of VM/RC hearts, as determined in serial transverse sections through left ventricles after staining of cell membranes, were also enlarged at . Genetic markers of hypertrophy were clearly elevated already in 6-to 8-week-old VM/RC hearts, for example, atrial natriuretic peptide was 44±10-fold and brain natriuretic peptide 4.4±0.6-fold over wt (P<0.001; Figure 6C ). Taken together, cardiac characterization of VM/RC mice indicated a synergistic (rather than an additive) behavior of the second mutation in amplifying the effects of 2 single mutations toward the development of myocardial hypertrophy and fibrosis. A similar heart phenotype as in VM/RC mice was observed in mice that are compound heterozygous for the benign VM and the malignant RW substitution (VM/RW) implying that the VM mutation also exacerbates HCM phenotypes of myosin mutations other than RC (Online Figure III) . Figure 7 ).
Impaired Systolic and Diastolic Function of Compound Heterozygous VM/RC Hearts
In addition to impaired systolic function of VM/RC hearts, left ventricular relaxation is also impaired (Table, Figure 7 ). Left ventricular end-diastolic volume was reduced (23.6±3.1 μL [VM/RC] versus 38.8±3.8 μL [VM/+]; P=0.01). Furthermore, maximum speed of pressure decay in VM/RC left ventricles were reduced (dp/dt min , −3387±648 versus −6832±730 mm Hg/s in VM/+; P<0.01) when 6 to 8 weeks old indicating diastolic dysfunction already before the development of significant hypertrophy and fibrosis (Figure 7 , bottom left). Moreover, β-adrenergic stimulation failed to enhance both slow contraction and relaxation of VM/RC hearts indicating a loss of cardiac reserve (Figure 7 , right).
Depressed Force Generation of VM/RC Myocardium
Heterozygous HCM causing mutations are known to enhance systolic heart function, and hypercontractility was also , maximal speed of pressure rise (dp/dt max ), and maximal speed of pressure decay (dp/dt min ) were not different among groups; n≥4 animals per genotype. D, Gross morphology and histological sections of 1-year-old wild-type (wt) mice compared with age-, strain-, and sex-matched homozygous mutants (VM/ VM). Heart sections were stained with hematoxylin and eosin (top) and with Sirius Red (bottom); bar, 100 μm. LVAW indicates left ventricular anterior wall thickness; LVEDD, left ventricular enddiastolic diameter; LVESD, left ventricular end-systolic diameter; and LVPW, left ventricular posterior wall thickness. July 7, 2014 found in RC/+ and RW/+ hearts. Therefore, we further dissected the cause of impaired systolic function in double heterozygous VM/RC mice by assessment of force production in isolated heart tissue. Left atria of 6-to 8-week-old VM/+ and VM/RC littermates were quickly excised, attached to a force transducer and kept in 37°C warm Tyrode's solution. After adjusting the pretension to 1 mN, tissue was electrically stimulated at a constant pace of 9 Hz to imitate physiological heart rate. Under these conditions, VM/RC tissue generated only 46% of the force produced by VM/+ tissue (0.18±0.04 versus 0.39±0.06 mN; P=0.01; Figure 7B ). Also the speed of force generation (9.2±1.7 versus 19.2±2.8 mN/s; P=0.01) and the speed of force decay were clearly reduced (−6.5±1.0 versus −15.2±2.3 mN/s; P<0.01). These findings suggest that impaired force production of double-mutant sarcomeres may underlie depressed pressure buildup of VM/RC hearts.
Transcriptional Profiling of VM/RC Hearts
For characterization of the molecular defects imposed by compound VM/RC heterozygous mutations, expression profiles of 3 VM/RC and 4 wt mouse hearts were assessed by DNA microarray analysis (Affymetrix Mouse Gene 2.0 ST). We identified 754 genes that were upregulated (534 genes) or downregulated (220 genes) in VM/RC hearts by >50% at a statistical significance of P<0.05. All differentially expressed genes (P<0.05) were assigned to respective gene ontology functional categories (gene ontology terms) and enrichment P values were calculated (Online Table I ). Among cellular components, differential gene expression was by far most significantly related to the gene ontology terms extracellular matrix (enrichment P value, P=1.99×10 −36 ) and collagen (P=7.2×10 −15 ). Gene ontology terms describing biological processes that were enriched for upregulated genes included the regulation of fibroblast proliferation (P=0.0001), cell death (P=0.00005), programmed cell death (P=0.00002), inflammatory (P=0.001), and immune responses (P=0.002) as well as the regulation of mitogen-activated protein kinase cascade (P=0.00003) and heart contraction (P=0.0002; Online Table I ). Furthermore, microarray analysis and quantitative polymerase chain reaction identified differential regulation of genes encoding proteins involved in calcium binding and calcium transport suggesting that disturbed calcium homeostasis may play a pathogenetic role in the development of the HCM phenotype in VM/RC hearts (Online Figures IV and V) .
Discussion
Genetically engineered mouse models carrying HCM causing β-MHC mutations in the mouse α-MHC gene closely resemble the cardiac pathology of the human disease. 14, 15, 18, 19 Here, we used such mice in an inbred genetic background to compare the phenotypic consequences of 3 different mutations. Similar to affected humans, RC/+ and RW/+ mice demonstrated slow progression of left ventricular hypertrophy during adolescence, interstitial fibrosis, and myofiber disarray at intact contractile function (Figure 2 ). Animals died early on when homozygous (Figure 4) . Although heterozygous or homozygous VM hearts were indistinguishable from wt hearts (Figures 2 and 3C and 3D, Online Figure II, Table) , the hypertrophic response could be exacerbated in VM/+ hearts either by cyclosporine treatment or by the combination of VM and RC mutations in a compound heterozygous model (VM/ RC). VM/RC mice developed cardiac hypertrophy and interstitial fibrosis to a degree similar to animals after transverse aortic banding ( Figure 6 ). 20 Cardiac contractile function was impaired early on and animals died prematurely at an average age of 62±8 weeks (Figures 5 and 7) .
The data indicate that the HCM stimulus caused by the VM mutation is much milder than that of the mutations RC and RW. Even homozygosity, which causes early lethality of RC/RC and RW/RW mice, did not induce signs of HCM in VM/VM hearts. Adverse effects attributable to the VM mutation only occurred in combination with other myosin mutations. However, in compound heterozygous mutants, the VM mutation severely boosted the morphological and functional HCM phenotype. These results indicate exceeding sensibility of the HCM causing RC mutation to additional variants within the cardiac myosin head. The individual genetic constitution of affected family members may bear great responsibility for the heterogeneity of resulting phenotypes as repeatedly described for the VM mutation. 6, [8] [9] [10] [11] [12] Presuming that our findings in mouse models can be extrapolated to humans, the data would suggest careful genetic testing of all individuals bearing a β-MHC mutation for additional genetic variants within the myosin head and possibly other sarcomere genes to stratify the individual risk and clinical management. Such analyses may be most important in patients carrying a benign β-MHC variant because the heart phenotype of mice carrying the VM mutation varied from no detectable changes to severe HCM and premature death contingent on the absence or presence of the RC mutation.
Unlike studies in humans, we observed little variation of measurements when characterizing the cardiac morphology and function of mouse models. Prediction of heart phenotypes based on age and genotype was always reliable recommending inbred mutant mouse lines for precise assessment of genotypephenotype correlations in HCM. Here, we engineered human β-MHC mutations into the mouse α-MHC gene because mouse hearts predominantly express the faster α-isoform. Although both isoforms share 93% identity in amino acid sequence, this is a drawback for the use of mice as genetic models of human HCM caused by β-MHC mutations. Nevertheless, knock-in mice heterozygous for the malignant RC and RW mutations in the α-MHC gene recapitulated morphological hallmarks of human HCM, such as gradual development of left ventricular hypertrophy, myofiber disarray, and fibrosis. Furthermore, functional analyses by echocardiography and left ventricular catheterization revealed hypercontractility of RC/+ and RW/+ mouse hearts ( Figures 2B and 7, Table 1 ), and previous studies in these and other α-MHC knock-in mouse models demonstrated enhanced actin filament sliding, increased ATPase activity and force production of the myosin head on the molecular level. 14, [21] [22] [23] These findings in mouse α-MHC closely match biophysical analyses using patient biopsies with HCM causing mutations in the β-isoform of MHC that described increased force, enhanced actin-myosin sliding velocities and actin-activated ATPase activity for a series of different mutations. [24] [25] [26] [27] In addition, Sommese et al 28 recently reported a 50% increase of intrinsic motor force by the RC mutation in an elegant in vitro study using recombinant human β-MHC produced in adenovirus-infected myoblasts. Given such parallels for homologous HCM causing mutations in human β-MHC and mouse α-MHC it seems likely that the morphological and functional phenotype of VM mutants observed in this study may reflect characteristics of human hearts bearing the VM mutation in β-MHC.
In combination with the malignant RC substitution the cardiac phenotype of VM mice changed from a normal healthy heart to severe hypertrophy, interstitial fibrosis, systolic and diastolic impairment of contractile function, and premature death. Mice heterozygous for 2 malignant HCM causing myosin mutations (RC/RW) died shortly after birth (data not shown). Human carriers of >1 HCM causing mutation have been reported to develop the disease earlier, with a higher degree of left ventricular hypertrophy and a higher incidence of sudden death events caused by a double dose effect. [29] [30] [31] Compound heterozygosity (different mutations , speed of pressure rise (dp/dt max ), and pressure decay (dp/dt min ) were measured at baseline (left) and during cardiac stimulation with dobutamine at increasing concentrations (right), n≥5 animals per genotype. B, Measurement of force generation in 6-to 8-week-old isolated left atria from heterozygous (VM/+) and compound heterozygous (VM/RC) mice. Force was measured at 1 mN pretension and electric stimulation at 9 Hz. dF/dt max indicates maximal speed of force generation; dF/dt min , maximal speed of force decay; and F max , maximal generated force. in homologous alleles) or double heterozygosity (2 mutations in different genes) is thought to occur in ≤5% of families with HCM. 29, 30, 32 The severe phenotype seen in VM/RC mouse hearts as well as in RC/RW and homozygous RC/RC and RW/RW mice suggests that in humans that carry 2 mutations ≥1 of the mutations must be mild. In fact, to date, no case has been reported with 2 β-MHC mutations that both are known to also cause HCM if expressed alone. A potential explanation for the synergistic effects of mutations in the myosin head may be the strong impact of the second myosin mutation on cardiac function (Figure 7) . While contractility is normal or even enhanced in VM/+ and RC/+ hearts, it is severely depressed in VM/RC hearts. Given the extensive development of interstitial fibrosis, it would be conceivable that compound VM and RC mutations induce a fundamental defect in the transmission of force from the sarcomeres to the extracellular matrix. Analyses of isolated tissue under defined workload suggested markedly reduced force production of double-mutant sarcomeres to underlie impaired hemodynamics ( Figure 7B ). Possibly, in a heterozygous situation the roughly 50% of wt myosin heads are essential to compensate functional changes inflicted by the mutant myosin heads. By implication, even a minor change of the wt myosin by a benign substitution would lead to severe consequences on contractile function.
Transcriptional profiling revealed that genes important for extracellular matrix and fibroblast proliferation are most frequently differentially expressed in VM/RC hearts (Online Table I ). These changes are consistent with our observation of severe myocardial fibrosis in these hearts at older age ( Figure 6) . A possible explanation for the massive induction of collagen is provided by the increased number of dying VM/ RC myocytes and subsequent replacement fibrosis (Online Figure VII) . The even distribution of singular terminal dUTP nick-end labeling-positive cells within the myocardium suggests that these cells may die by apoptosis. This assertion is substantiated by the over-representation of upregulated genes in gene ontology categories relevant for the regulation of cell death (P=0.00005) and apoptotic processes (P=0.00003; Online Table I, Online Figure VI) .
Gene array analyses further provided evidence for involvement of pathogenic factors other than cell death in increased collagen production of VM/RC hearts. (1) We previously found transforming growth factor-β, which induces the synthesis of matrix molecules, to be required for the development of cardiac fibrosis in RW/+ mouse hearts by mediating nonmyocyte proliferation. 15 In this study, microarray and quantitative polymerase chain reaction analyses detected upregulation of transforming growth factor-β and transforming growth factor-β receptors in VM/RC hearts suggesting that increased transforming growth factor-β signaling may also trigger fibrosis in VM/RC myocardium (Online Table II ). (2) Along these lines, transcriptional profiling of VM/RC mouse hearts further hints at a possible involvement of inflammatory responses and immunologic processes in fibrotic myocardial remodeling (Online Table I ). (3) Heart sections of an independent mouse model that develops severe dilated cardiomyopathy attributable to an Arg9Cys mutation in phospholamban revealed clearly more terminal dUTP nick-end labeling-positive cells than VM/RC hearts suggesting additional mechanisms to contribute to the high level of myocardial fibrosis observed in the latter (Online Figure VII) . (4) Measurements of cardiac function indicated severe systolic and diastolic impairment of VM/RC left ventricles (Figure 7) . Depressed hemodynamics would induce adverse myocardial remodeling attributable to both increased wall stress of ventricles and neurohumoral activation, that is, stimulation of the sympathetic system and the renin-angiotensin-aldosterone system.
In mice, there are 3 pertinent studies with multiple HCM causing sarcomere mutations though this is the first report on compound heterozygous myosin mutants. Tsoutsman et al 33 characterized mice bearing a combination of the α-MHC Arg403Gln mutation plus a transgene expressing the HCM causing Gly203Ser troponin I mutation in the mouse heart. These animals developed dilated cardiomyopathy, heart failure, and death within 3 weeks after birth. Also mice homozygous for an HCM causing loss of function mutation in the gene for cardiac myosin-binding protein C showed neonatal onset of progressive dilated cardiomyopathy. 34 These animals lived for more than a year and heterozygotes developed just mild symptoms of HCM. Based on these observations, it seemed that an increased gene dosage or the combination of 2 cues that cause HCM would foster a dilated phenotype of the heart. Thus, it seemed likely that the combination of 2 HCM causing myosin mutations may also lead to cardiac dilatation, particularly in the light of β-MHC mutations that have been identified to induce dilated cardiomyopathy, such as the substitutions Ser532Pro and Phe764Leu. 35 Nevertheless, VM/RC mice developed pure hypertrophy and typical features of HCM indicating that the combination of 2 heterozygous HCM causing mutations do not necessarily foster dilatation of the heart.
The comparison of 3 different knock-in mouse lines showed that the VM mutation seems to be benign. However, the VM mutation severely remodels the heart in a more than additive manner when combined with other heterozygous HCM causing myosin mutations. Along these lines, the combination of 2 malignant myosin mutations in homozygous RC/RC or RW/ RW hearts is lethal. Genetically engineered mice seem to be suitable to assess the severity of human β-MHC mutations. The bold phenotypic boost in double-mutant mice further suggests compound mutants for assessment of severity. This strategy seems particularly useful for evaluating the consequences of benign mutations that do not induce significant phenotypes if expressed alone.
If every patient with HCM would carry 1 single sarcomere mutation and the prevalence of HCM is 1:500, 36 the statistical risk to inherit an HCM causing mutation from either parent would be in the range of 1:1 million. However, compound heterozygosity or double heterozygosity have been described in up to 5% of families with HCM, 29, [31] [32] [33] 37 and the 1000 Genomes Project database revealed multiple pathogenic mutations of sarcomeric genes in 5 of 1092 individuals suggesting that the majority of these gene variants would not be disease causing if expressed alone. 38 Nevertheless, they may severely impact the severity of HCM as this study has shown in mice. A synthetic gain of phenotype would uncover relatively mild mutations and also explain the occasionally striking phenotypic heterogeneity among individuals carrying the same HCM causing mutation. Finally, it would strongly suggest genetic testing of every HCM patient for additional genetic variants within sarcomere genes, to stratify the individual risk and clinical management.
